image
Healthcare - Biotechnology - NASDAQ - IE
$ 30.285
-3.41 %
$ 4.99 B
Market Cap
13.79
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALKS stock under the worst case scenario is HIDDEN Compared to the current market price of 30.3 USD, Alkermes plc is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALKS stock under the base case scenario is HIDDEN Compared to the current market price of 30.3 USD, Alkermes plc is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALKS stock under the best case scenario is HIDDEN Compared to the current market price of 30.3 USD, Alkermes plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALKS

image
$36.0$36.0$35.0$35.0$34.0$34.0$33.0$33.0$32.0$32.0$31.0$31.0$30.0$30.0$29.0$29.0$28.0$28.0$27.0$27.0$26.0$26.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
1.56 B REVENUE
-6.36%
421 M OPERATING INCOME
1.57%
367 M NET INCOME
3.18%
439 M OPERATING CASH FLOW
9.41%
-111 M INVESTING CASH FLOW
-208.61%
-494 M FINANCING CASH FLOW
-70.56%
307 M REVENUE
-28.72%
13.8 M OPERATING INCOME
-91.52%
22.5 M NET INCOME
-84.67%
98.8 M OPERATING CASH FLOW
-48.10%
9.1 M INVESTING CASH FLOW
165.60%
747 K FINANCING CASH FLOW
100.27%
Balance Sheet Alkermes plc
image
Current Assets 1.42 B
Cash & Short-Term Investments 752 M
Receivables 390 M
Other Current Assets 274 M
Non-Current Assets 640 M
Long-Term Investments 73.1 M
PP&E 312 M
Other Non-Current Assets 255 M
36.57 %18.95 %13.34 %3.56 %15.17 %12.42 %Total Assets$2.1b
Current Liabilities 465 M
Accounts Payable 45.6 M
Short-Term Debt 6.17 M
Other Current Liabilities 413 M
Non-Current Liabilities 125 M
Long-Term Debt 0
Other Non-Current Liabilities 125 M
7.73 %70.00 %21.23 %Total Liabilities$590.6m
EFFICIENCY
Earnings Waterfall Alkermes plc
image
Revenue 1.56 B
Cost Of Revenue 245 M
Gross Profit 1.31 B
Operating Expenses 892 M
Operating Income 421 M
Other Expenses 53.6 M
Net Income 367 M
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m002b(245m)1b(892m)421m(54m)367mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.25% GROSS MARGIN
84.25%
27.00% OPERATING MARGIN
27.00%
23.57% NET MARGIN
23.57%
25.06% ROE
25.06%
17.86% ROA
17.86%
22.09% ROIC
22.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alkermes plc
image
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 367 M
Depreciation & Amortization 28.5 M
Capital Expenditures -33.5 M
Stock-Based Compensation 96.6 M
Change in Working Capital -98.2 M
Others 13.3 M
Free Cash Flow 406 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alkermes plc
image
Wall Street analysts predict an average 1-year price target for ALKS of $35 , with forecasts ranging from a low of $25 to a high of $40 .
ALKS Lowest Price Target Wall Street Target
25 USD -17.45%
ALKS Average Price Target Wall Street Target
35 USD 15.57%
ALKS Highest Price Target Wall Street Target
40 USD 32.08%
Price
Max Price Target
Min Price Target
Average Price Target
4040383836363434323230302828262624242222Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Alkermes plc
image
Sold
0-3 MONTHS
245 K USD 1
3-6 MONTHS
18 M USD 3
6-9 MONTHS
2.08 M USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations. zacks.com - 2 weeks ago
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The ongoing phase 3 ENLIGHTEN-Youth trial aims to evaluate LYBALVI's efficacy and safety in pediatric patients, with a primary completion date of September 2026. Long-term data indicates minimal weight gain with LYBALVI, addressing a major concern with mental health medications and supporting its market potential. seekingalpha.com - 2 weeks ago
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 weeks ago
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Blair Jackson - Executive Vice President and Chief Operating Officer Craig Hopkinson - Chief Medical Officer Conference Call Participants Joseph Thome - TD Cowen Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Uy Ear - Mizuho Securities Joel Beatty - Baird David Hoang - Deutsche Bank Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to Alkermes' First Quarter 2025 Financial Results Conference Call. seekingalpha.com - 2 weeks ago
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago. zacks.com - 2 weeks ago
Alkermes plc Reports First Quarter 2025 Financial Results —    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN , May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. prnewswire.com - 2 weeks ago
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) – Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and the Positive Impact of Treatment on Their Lives – DUBLIN , April 30, 2025 /PRNewswire/ -- A new online survey conducted by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), sought to understand utilization of and experiences with treatment among 300 adults between ages 21-64 who self-identify as having been diagnosed with alcohol use disorder (AUD) by a healthcare provider. The survey showed that the path to AUD diagnosis can be challenging and often driven by negative consequences, but treatment may positively impact people living with AUD. prnewswire.com - 2 weeks ago
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Alkermes to Report First Quarter Financial Results on May 1, 2025 DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. prnewswire.com - 1 month ago
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. prnewswire.com - 1 month ago
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia. zacks.com - 1 month ago
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia DUBLIN , April 1, 2025 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness. prnewswire.com - 1 month ago
8. Profile Summary

Alkermes plc ALKS

image
COUNTRY IE
INDUSTRY Biotechnology
MARKET CAP $ 4.99 B
Dividend Yield 0.00%
Description Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Contact Connaught House, Dublin, 4 https://www.alkermes.com
IPO Date July 16, 1991
Employees 1800
Officers Mr. David Joseph Gaffin J.D. Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary Mr. C. Todd Nichols Senior Vice President & Chief Commercial Officer Mr. Samuel J. Parisi Interim Principal Accounting Officer & Vice President of Finance Mr. Blair C. Jackson Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer Mr. Richard F. Pops Chairman & Chief Executive Officer Mr. Thomas Harvey Chief Information Officer & Senior Vice President of IT Dr. Craig C. Hopkinson M.D. Executive Vice President of Research & Development and Chief Medical Officer Mr. Stephen Schiavo Senior Vice President & Chief Human Resources Officer Mr. Peter Norman Senior Vice President of Policy & Government Relations Ms. Sandra Coombs Senior Vice President of Corporate Affairs & Investor Relations